Literature DB >> 10466805

Tissue culture infectivity of different strains of infectious bursal disease virus is determined by distinct amino acids in VP2.

Egbert Mundt1.   

Abstract

Two types of strains of serotype I of infectious bursal disease virus (IBDV) have been described, on the basis of their ability (IBDV-TC) or inability (IBDV-BU) to infect chicken embryonic cells in culture. However, both types infect B lymphocytes in the bursa of Fabricius of young chickens. To determine the molecular basis for tissue culture infectivity, virus recombinants with chimeric segments A were constructed from IBDV-TC and IBDV-BU by reverse genetics. The region responsible for the different phenotypes was located in VP2. Site-directed mutagenesis identified single amino acids that are responsible for the restriction in infectivity. However, the appropriate amino acid exchanges are strain-specific.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466805     DOI: 10.1099/0022-1317-80-8-2067

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Full-length sequence analysis of four IBDV strains with different pathogenicities.

Authors:  Daniel Petkov; Erich Linnemann; Darrell R Kapczynski; Holly S Sellers
Journal:  Virus Genes       Date:  2006-08-22       Impact factor: 2.332

2.  The 2.6-Angstrom structure of infectious bursal disease virus-derived T=1 particles reveals new stabilizing elements of the virus capsid.

Authors:  Damià Garriga; Jordi Querol-Audí; Fernando Abaitua; Irene Saugar; Joan Pous; Núria Verdaguer; José R Castón; José F Rodriguez
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Molecular determinants of virulence, cell tropism, and pathogenic phenotype of infectious bursal disease virus.

Authors:  M Brandt; K Yao; M Liu; R A Heckert; V N Vakharia
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Sequence variability and evolution of the terminal overlapping VP5 gene of the infectious bursal disease virus.

Authors:  Martín Hernández; Pedro Villegas; Diego Hernández; Alejandro Banda; Leticia Maya; Valeria Romero; Gonzalo Tomás; Ruben Pérez
Journal:  Virus Genes       Date:  2010-05-01       Impact factor: 2.332

5.  Rescue of very virulent and mosaic infectious bursal disease virus from cloned cDNA: VP2 is not the sole determinant of the very virulent phenotype.

Authors:  H J Boot; A A ter Huurne; A J Hoekman; B P Peeters; A L Gielkens
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Exchange of the C-terminal part of VP3 from very virulent infectious bursal disease virus results in an attenuated virus with a unique antigenic structure.

Authors:  Hein J Boot; A Agnes H M ter Huurne; Arjan J W Hoekman; Jan M Pol; Arno L J Gielkens; Ben P H Peeters
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Sequence analysis of the variable VP2 gene of infectious bursal disease viruses passaged in Vero cells.

Authors:  Hyuk Moo Kwon; Soo Joung Kim
Journal:  Virus Genes       Date:  2004-04       Impact factor: 2.332

8.  Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus.

Authors:  Tobias Letzel; Fasseli Coulibaly; Felix A Rey; Bernard Delmas; Erik Jagt; Adriaan A M W van Loon; Egbert Mundt
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Overexpression of recombinant infectious bursal disease virus (IBDV) capsid protein VP2 in the middle silk gland of transgenic silkworm.

Authors:  Hanfu Xu; Lin Yuan; Feng Wang; Yuancheng Wang; Riyuan Wang; Chunnuan Song; Qingyou Xia; Ping Zhao
Journal:  Transgenic Res       Date:  2014-08-09       Impact factor: 2.788

10.  Both genome segments contribute to the pathogenicity of very virulent infectious bursal disease virus.

Authors:  Olivier Escaffre; Cyril Le Nouën; Michel Amelot; Xavier Ambroggio; Kristen M Ogden; Olivier Guionie; Didier Toquin; Hermann Müller; Mohammed R Islam; Nicolas Eterradossi
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.